Last reviewed · How we verify
Risk of asthma in offspring — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Risk of asthma in offspring (Risk of asthma in offspring) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Risk of asthma in offspring TARGET | Risk of asthma in offspring | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Risk of asthma in offspring CI watch — RSS
- Risk of asthma in offspring CI watch — Atom
- Risk of asthma in offspring CI watch — JSON
- Risk of asthma in offspring alone — RSS
Cite this brief
Drug Landscape (2026). Risk of asthma in offspring — Competitive Intelligence Brief. https://druglandscape.com/ci/risk-of-asthma-in-offspring. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab